Literature DB >> 2527991

The economic impact of the rheumatic diseases in the United States.

W Felts1, E Yelin.   

Abstract

We review the literature and analyze data from the National Health Interview Survey to provide estimates of the economic cost and social impacts of the rheumatic diseases in the United States. Rheumatic diseases had an economic impact in 1980 of 21 billion dollars due to expenditures for health care and lost wages, an amount equal to 1% of gross national product. These conditions are responsible for 5% of all hospital discharges, 10% of all hospital procedures, and 9% of all physician visits. They are also responsible for over 2 million persons being unable to do major activities, for 5 million being limited in other ways, and for at least 1 million being severely limited in the ability to perform activities of daily living. As great these impacts would appear to be, they are likely to grow since the aging of the population increases both the prevalence and severity of impact of the rheumatic diseases.

Entities:  

Mesh:

Year:  1989        PMID: 2527991

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  26 in total

Review 1.  Anti-TNF agents for rheumatoid arthritis.

Authors:  H E Seymour; A Worsley; J M Smith; S H Thomas
Journal:  Br J Clin Pharmacol       Date:  2001-03       Impact factor: 4.335

Review 2.  Predictive factors of work disability in rheumatoid arthritis: a systematic literature review.

Authors:  E M de Croon; J K Sluiter; T F Nijssen; B A C Dijkmans; G J Lankhorst; M H W Frings-Dresen
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

Review 3.  International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review.

Authors:  Hubertus Rosery; Rito Bergemann; Stefanie Maxion-Bergemann
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  The direct and indirect costs of the chronic management of osteoporosis: a prospective follow-up of 3440 active subjects.

Authors:  V Rabenda; C Manette; R Lemmens; A-M Mariani; N Struvay; J-Y Reginster
Journal:  Osteoporos Int       Date:  2006-06-24       Impact factor: 4.507

5.  A randomized, double-blind, placebo-controlled clinical trial using a low-frequency magnetic field in the treatment of musculoskeletal chronic pain.

Authors:  Alex W Thomas; Karissa Graham; Frank S Prato; Julia McKay; Patricia Morley Forster; Dwight E Moulin; Sesh Chari
Journal:  Pain Res Manag       Date:  2007       Impact factor: 3.037

6.  Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients.

Authors:  A Boonen; A Chorus; H Miedema; D van der Heijde; H van der Tempel; S van der Linden
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

7.  Profile of arthritis disability.

Authors:  L M Verbrugge; L Juarez
Journal:  Public Health Rep       Date:  2001       Impact factor: 2.792

8.  Labour force participation among patients with rheumatoid arthritis.

Authors:  A M Chorus; H S Miedema; C J Wevers; S van Der Linden
Journal:  Ann Rheum Dis       Date:  2000-07       Impact factor: 19.103

Review 9.  The costs of rheumatoid arthritis.

Authors:  S H Allaire; M J Prashker; R F Meenan
Journal:  Pharmacoeconomics       Date:  1994-12       Impact factor: 4.981

Review 10.  A review of the direct costs of rheumatoid arthritis: managed care versus fee-for-service settings.

Authors:  D P Lubeck
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.